^
Association details:
| Biomarker: | ALK expression + RSRC1-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique
Published date:
08/13/2023
Excerpt:
Postoperative pathological analysis indicated invasive adenocarcinoma with mainly mucinous type and partial micropapillary type in left lower lung. Minimally invasive adenocarcinoma was seen in left upper lung, with mainly acinar type. NGS detected a novel RSRC1-ALK (R6: A20) fusion in left lower lobe sample...Immunohistochemistry showed ALK positive expression in lung. For the treatment, the patient received ensartinib hydrochloride with a dose of 225 mg per day. He was in a state of progression-free survival for at least 24 months in follow-up with no complications.
DOI:
10.1016/j.cancergen.2023.08.003
